Zobrazeno 1 - 10
of 551
pro vyhledávání: '"BUZDAR, A"'
Publikováno v:
Holland-Frei Cancer Medicine
Publikováno v:
BMJ: British Medical Journal, 2003 Nov 01. 327(7422), 1050-1050.
Externí odkaz:
https://www.jstor.org/stable/25457664
Autor:
Paul E. Goss, James N. Ingle, Hu Li, Aman U. Buzdar, Matthew P. Goetz, Junmei Cairns, Richard M. Weinshilboum, Tanda M. Dudenkov, Erin E. Carlson, Matthew J. Ellis, Krishna R. Kalari, Liewei Wang, Jie Na, Barbara Goodnature, Mark E. Robson, Lois E. Shepherd, Mehrab Ghanat Bari
Publikováno v:
JCI Insight, Vol 5, Iss 16 (2020)
JCI Insight
JCI Insight
Aromatase inhibitors (AIs) reduce breast cancer recurrence and prolong survival, but up to 30% of patients exhibit recurrence. Using a genome-wide association study of patients entered on MA.27, a phase III randomized trial of anastrozole versus exem
Autor:
Lee Trani, Judy C. Boughey, MJ Ellis, Vera J. Suman, Aman U. Buzdar, K. K. Hunt, Mark A. Watson, Malachi Griffith, Jasreet Hundal, Rebecca Aft, A. M. Leitch, Obi L. Griffith, Robert Lesurf, Funda Meric-Bernstam, Elaine R. Mardis, David M. Ota, Gary Unzeitig
Publikováno v:
Annals of Oncology. 28:1070-1077
Background HER2 (ERBB2) gene amplification and its corresponding overexpression are present in 15–30% of invasive breast cancers. While HER2-targeted agents are effective treatments, resistance remains a major cause of death. The American College o
Autor:
Clark V. Williard, Liewei Wang, Tracy L. Pietrzak, Matthew P. Goetz, Anthony Batzler, Erin E. Carlson, Yusuke Nakamura, Donald W. Northfelt, Michiaki Kubo, Gregory D. Jenkins, Alvaro Moreno-Aspita, Irada Ibrahim-zada, Krishna R. Kalari, Richard M. Weinshilboum, Aman U. Buzdar, Poulami Barman, Mark E. Robson, Tanda M. Dudenkov, James N. Ingle
Publikováno v:
Breast Cancer Research and Treatment. 164:189-199
Estrone (E1), the major circulating estrogen in postmenopausal women, promotes estrogen-receptor positive (ER+) breast tumor growth and proliferation. Two major reactions contribute to E1 plasma concentrations, aromatase (CYP19A1) catalyzed E1 synthe
Autor:
MP Goetz, Aman U. Buzdar, T Dudenkov, Krishna R. Kalari, J Cairns, Richard M. Weinshilboum, Paul E. Goss, MJ Ellis, L Wang, Mark E. Robson, JN Ingle, Michiaki Kubo, Lois E. Shepherd
Publikováno v:
Cancer Research. 77:PD1-04
BACKGROUND: Based on prospective clinical trials, there is no evidence for differences in efficacy between the 3 aromatase inhibitors (AIs) anastrozole, exemestane, and letrozole. The purpose of this study was to identify germline genetic variants as
Autor:
Jonas Bergh, L Strobbe, C Hanusch, Mitchell Dowsett, Ivana Sestak, Jack Cuzick, R Smith, John F. Forbes, A Howell, Aman U. Buzdar, Angelo Raffaele Bianco, Patrick Neven
Publikováno v:
Cancer Research. 77:P2-09
Background: Previous reports from the Anastrozole Tamoxifen Alone or in Combination (ATAC) trial have shown significantly prolonged disease-free survival, lower rates of recurrence and distant recurrence, and reduced contralateral breast cancer in pa
Autor:
Gretchen Kimmick, Arti Hurria, Aminah Jatoi, Harvey J. Cohen, Heidi D. Klepin, Jacqueline Lafky, Aman U. Buzdar, Jeff A. Sloan, Vera J. Suman, Clifford A. Hudis, Ann H. Partridge, Donald A. Berry, Jared C. Foster, Eric P. Winer, Drew K. Seisler, Marc L. Citron, Hyman B. Muss, Rachel A. Freedman, Lisa A. Carey, Lawrence N. Shulman
Publikováno v:
Breast Cancer Research and Treatment. 161:363-373
We examined acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) events among 9679 women treated for breast cancer on four adjuvant Alliance for Clinical Trials in Oncology trials with >90 months of follow-up in order to better characteriz
Autor:
Funda Meric-Bernstam, Matthew J. Ellis, Kelly K. Hunt, Judy C. Boughey, Gary Unzeitig, Aman U. Buzdar, Melanie Royce, Vera J. Suman, A. M. Leitch
Importance Pathologic complete response rate (pCR), the primary end point of the ACOSOG (American College of Surgeons Oncology Group) Z1041 (Alliance) trial, and disease-free survival (DFS) and overall survival (OS) in women with operable HER2-positi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d0aaa6ab3add35a83133c0cb9cba406a
https://europepmc.org/articles/PMC6331049/
https://europepmc.org/articles/PMC6331049/
Autor:
Judy C. Boughey, Gary Unzeitig, VJ Suman, MJ Ellis, K. K. Hunt, Ewer, Aman U. Buzdar, Funda Meric-Bernstam, A. M. Leitch, Melanie Royce
Publikováno v:
Cancer Research. 76:P1-14
Background ACOSOG Z1041 (Alliance) found pathological complete response rates in women with operable HER2-positive breast cancer were similar with FEC → P+T (Arm 1) and P+T → FEC+T (Arm 2) where treatment was administered as 5-FU 500 mg/m2, epiru